Zobrazeno 1 - 10
of 123
pro vyhledávání: '"PER-OLOF ERIKSSON"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract This study examined the association between hearing loss in sporadic vestibular schwannoma patients and the proteome of perilymph (PL), cerebrospinal fluid (CSF), and vestibular schwannoma. Intraoperative sampling of PL and of CSF, and biops
Externí odkaz:
https://doaj.org/article/8949650985cd4a5094ef16e889900805
Autor:
Ola Fjellström, Sibel Akkaya, Hans-Georg Beisel, Per-Olof Eriksson, Karl Erixon, David Gustafsson, Ulrik Jurva, Daiwu Kang, David Karis, Wolfgang Knecht, Viveca Nerme, Ingemar Nilsson, Thomas Olsson, Alma Redzic, Robert Roth, Jenny Sandmark, Anna Tigerström, Linda Öster
Publikováno v:
PLoS ONE, Vol 10, Iss 1, p e0113705 (2015)
Activated factor XI (FXIa) inhibitors are anticipated to combine anticoagulant and profibrinolytic effects with a low bleeding risk. This motivated a structure aided fragment based lead generation campaign to create novel FXIa inhibitor leads. A virt
Externí odkaz:
https://doaj.org/article/1a2cc35337574e84979292e3f9e6ec05
Autor:
Per-Olof Eriksson, Emil Aaltonen, Rodrigo Petoral, Petter Lauritzson, Hideki Miyazaki, Kristian Pietras, Sven Månsson, Lennart Hansson, Peter Leander, Oskar Axelsson
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e107762 (2014)
The current study was carried out to test the potential of a new nanomaterial (Spago Pix) as a macromolecular magnetic MR contrast agent for tumor detection and to verify the presence of nanomaterial in tumor tissue. Spago Pix, synthesized by Spago N
Externí odkaz:
https://doaj.org/article/3ab71b71461c429a85bb6bf7a77e9a67
Publikováno v:
PLoS ONE, Vol 19, Iss 6, p e0304184 (2024)
Vestibular schwannoma can cause vestibular dysfunction; however, conflicting evidence exists regarding whether this affects the incidence of fall-related injuries in this patient population. This matched cross-sectional and cohort study assess the ri
Externí odkaz:
https://doaj.org/article/b4b81f0cb23148deb46bdc55a494d641
Autor:
Johannes Reiner, Johanna Thiery, Jascha Held, Peggy Berlin, Jolanta Skarbaliene, Brigitte Vollmar, Robert Jaster, Per‐Olof Eriksson, Georg Lamprecht, Maria Witte
Publikováno v:
Annals of the New York Academy of Sciences. 1514:132-141
Short bowel syndrome can occur after extensive intestinal resection, causing intestinal insufficiency or intestinal failure, which requires long-term parenteral nutrition. Glucagon-like peptide-2 (GLP-2) pharmacotherapy is now clinically used to redu
Autor:
Maria Witte, Wayne Russell, Jolanta Skarbaliene, Jascha Held, Jonathan Griffin, Peggy Berlin, Johanna Thiery, Per-Olof Eriksson, Mark Berner-Hansen, Robert Jaster, Luise Ehlers, Brigitte Vollmar, Georg Lamprecht, Johannes Reiner
Publikováno v:
Journal of Parenteral and Enteral Nutrition. 46:1107-1118
Background Extensive intestinal resection may lead to short bowel syndrome resulting in intestinal insufficiency or intestinal failure (IF). Intestinal insufficiency and IF involve deficiency of the proglucagon-derived hormones, GLP-1 and GLP-2. Two
Autor:
Simon C. C. Lucas, Ulf Börjesson, Mark J. Bostock, John Cuff, Fredrik Edfeldt, Kevin J. Embrey, Per-Olof Eriksson, Andrea Gohlke, Anders Gunnarson, Michael Lainchbury, Alexander G. Milbradt, Rachel Moore, Philip B. Rawlins, Ian Sinclair, Christopher Stubbs, R. Ian Storer
Publikováno v:
RSC Med Chem
Fragment based drug discovery is a critical part of the lead generation toolbox and relies heavily on a readily available, high quality fragment library. Over years of use, the AstraZeneca fragment set had become partially depleted and instances of c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::446ddff84fa8641f08a20b101425dc2e
https://europepmc.org/articles/PMC9491351/
https://europepmc.org/articles/PMC9491351/
Publikováno v:
Diabetes. 71
Amylin improves glucose homeostasis through at least three distinct mechanisms of action, including prevention of the postprandial rise in plasma glucagon, slowing of gastric emptying, and increased satiety, leading to decreased caloric intake and po
Autor:
MINNA B. OLSEN, ULRIKE HÖVELMANN, JON GRIFFIN, KIM M. KNUDSEN, PER-OLOF ERIKSSON, MIKKEL A. AGERSNAP
Publikováno v:
Diabetes. 71
Dapiglutide is a first-in-class peptide with dual activity on the GLP-1 and GLP-2 receptors and with potential to treat several metabolic/gastrointestinal (GI) diseases. In a multiple ascending dose cohort trial, 40 healthy subjects (mean BMI 24.6 kg
Autor:
Birgitta Karlsson Svalstedt, Anders Thelin, Annika Wellner, Johanna Vinblad, Margareta Herslöf, David Gustafsson, Yantao Chen, Cristian Bodin, Ola Fjellström, Stefan Blaho, Jenny Sandmark, Carina Johansson, Birgitta Rosengren, Sofia Martinsson, Tomas Fex, Jonas Boström, Andreas Moberg, Tomas Akerud, Emma Evertsson, Bingze Xu, Ryan Hicks, Magnus Althage, Emelie Jarkvist, Wolfgang Knecht, Per-Olof Eriksson, Marianne Ridderström, Ann-Margret Östlund-Lindqvist, Anna Tigerström, Anders Dahlén, Anne Legnehed, Thomas Antonsson, Alan Sabirsh, Inge Kalies, Fredrik Kartberg
Publikováno v:
J Biol Chem
Increased plasma concentrations of lipoprotein(a) (Lp(a)) are associated with an increased risk for cardiovascular disease. Lp(a) is composed of apolipoprotein(a) (apo(a)) covalently bound to apolipoprotein B of low-density lipoprotein (LDL). Many of